ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

ClinicalTrials.gov ID: NCT02072824

Public ClinicalTrials.gov record NCT02072824. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures

Study identification

NCT ID
NCT02072824
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
175 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Pregabalin Dose Level 1 Drug
  • Pregabalin Dose Level 2 Drug

Drug

Eligibility (public fields only)

Age range
1 Month to 3 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 15, 2014
Primary completion
Mar 12, 2018
Completion
Mar 12, 2018
Last update posted
Jan 19, 2021

2014 – 2018

United States locations

U.S. sites
5
U.S. states
2
U.S. cities
4
Facility City State ZIP Site status
Pediatric Epilepsy Center of Central Florida Orlando Florida 32819
Pediatric Neurology, PA Orlando Florida 32819
Pediatric Epilepsy & Neurology Specialists, PA Tampa Florida 33609
The University of Texas Health Science Center at Houston Houston Texas 77030
Road Runner Research, Ltd. San Antonio Texas 78249

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02072824, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2021 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02072824 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →